Table II.

Human studies.

Study, year	N	Cell type	Follow-up time (months)	Study design	Evidence level	(Refs.)
Rigotti, 2007	20	SVF	30	Case series	IV	(53)
Yoshimura, 2008	40	SVF	<42	Retrospective cohort	IV	(30)
Yoshimura, 2008	6	SVF	9–13	Prospective cohort	III	(70)
Yoshimura, 2010	15	SVF	<18	Case series	IV	(71)
Yoshimura, 2008	2	SVF	12	Case report	V	(72)
Asano, 2010	26	ADSC	Unknown	Case series	IV	(54)
Kamakura, 2010	20	SVF	9	Single-arm clinical trial	III	(73)
Tiryaki, 2011	29	SVF	<36	Case series	IV	(74)
Sterodimas, 2011	20	SVF	<18	Randomized clinical trial	III	(75)
Wang, 2012	18	SVF	<6	Case series	IV	(76)
Perez-Cano, 2012	67	SVF	<12	Single-arm clinical trial	III	(77)
Castro-Govea, 2012	1	SVF	<12	Case report	V	(78)
Li, 2013	38	SVF	6	Retrospective cohort	IV	(84)
Peltoniemi, 2013	18	SVF	<6	Clinical trial	III	(79)
Tanikawa, 2013	14	SVF	<12	Randomized clinical trial	II	(80)
Kølle, 2013	20	ADSC	4	Randomized clinical trial	II	(55)
Wang, 2015	12	SVF	<6	Case series	IV	(81)
Domenis, 2015	20	ADSC	<12	Prospective cohort	IV	(82)
Jung, 2015	5	SVF	<12	Prospective cohort	IV	(83)

Evidence levels were used based on the hierarchical system of classifying evidence (85) as follows: I, high-quality prospective cohort study with adequate power or systematic review of these studies; II, lesser quality prospective cohort, retrospective cohort study, untreated controls from a randomised control trial, or systematic review of these studies; III, case-control study or systematic review of these studies; IV, case series; V, expert opinion; case report or clinical example; or evidence based on physiology, bench research, or ‘first principles’. N, number of patients; SVF, stromal vascular fraction; ASC, adipose-derived stem cells; <, up to.